Compare · BMY vs REGN
BMY vs REGN
Side-by-side comparison of Bristol-Myers Squibb Company (BMY) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMY and REGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- BMY is the larger of the two at $129.66B, about 1.3x REGN ($98.84B).
- REGN has been more active in the news (18 items in the past 4 weeks vs 14 for BMY).
- Both have 25 recent analyst ratings on file.
- Company
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $129.66B
- $98.84B
- 1M return
- +4.70%
- -
- 1Y return
- +35.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- News (4w)
- 14
- 18
- Recent ratings
- 25
- 25
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Latest BMY
- Bristol Myers Squibb Announces Evolution of Research & Development Organization
- Director Haller Julia A sold $240,578 worth of shares (3,800 units at $63.31), decreasing direct ownership by 11% to 30,279 units (SEC Form 4)
- Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
- Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026
- EVP, Chief Commercial Officer Lenkowsky Adam converted options into 7,522 shares and covered exercise/tax liability with 3,848 shares, increasing direct ownership by 19% to 23,380 units (SEC Form 4)
- Chief Executive Officer Boerner Christopher S. converted options into 2,964 shares, acquired 406 shares and covered exercise/tax liability with 1,724 shares, increasing direct ownership by 8% to 23,097 units (SEC Form 4)
- EVP, Chief Supply Chain & Ops Shanahan Karin converted options into 6,281 shares and covered exercise/tax liability with 3,213 shares, increasing direct ownership by 12% to 28,956 units (SEC Form 4)
- EVP, Chief Digital & Tech Off. Meyers Gregory Scott converted options into 6,281 shares and covered exercise/tax liability with 2,665 shares, increasing direct ownership by 12% to 33,977 units (SEC Form 4)
- 2027 Could Finally Be the Year Cancer Is on the Ropes!
- SEC Form 10-Q filed by Bristol-Myers Squibb Company
Latest REGN
- POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
- SVP Controller Pitofsky Jason exercised 3,883 shares at a strike of $640.66 and sold $3,827,159 worth of shares (4,062 units at $942.19) (SEC Form 4)
- Co-Chief Scientific Officer Murphy Andrew J gifted 1,054 shares, decreasing direct ownership by 2% to 46,779 units (SEC Form 4)
- SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.
- Director Zoghbi Huda Y exercised 7,439 shares at a strike of $380.95 and sold $7,219,274 worth of shares (7,439 units at $970.46) (SEC Form 4)
- Director Sing George L exercised 15,269 shares at a strike of $378.77 and sold $20,376,358 worth of shares (21,129 units at $964.38), decreasing direct ownership by 19% to 25,147 units (SEC Form 4)
- Director Poon Christine A exercised 7,830 shares at a strike of $376.69 and sold $7,587,958 worth of shares (7,830 units at $969.09) (SEC Form 4)
- EVP Finance CFO Fenimore Christopher R. exercised 6,000 shares at a strike of $381.92, covered exercise/tax liability with 4,243 shares and gifted 15 shares, increasing direct ownership by 9% to 21,726 units (SEC Form 4)
- EVP General Counsel and Secret Larosa Joseph J exercised 12,283 shares at a strike of $381.92, covered exercise/tax liability with 8,686 shares and sold $4,311,890 worth of shares (4,466 units at $965.49), decreasing direct ownership by 2% to 38,906 units (SEC Form 4)